Beijing Wandong Medical Technology (600055) Fundamentals 2026 — Revenue Analysis | SniperIQ
Beijing Wandong Medical Technology (600055) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of ¥7.4B, trading at ¥10.46 on the SHH. This SniperIQ fundamentals page covers Beijing Wandong Medical Technology's valuation, profitability (net margin -20.2%), revenue (¥1.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Beijing Wandong Medical Technology's market cap?
Beijing Wandong Medical Technology (600055) has a market capitalization of approximately ¥7.4B, trading at ¥10.46 on the SHH. Market cap moves with the live share price.
What is Beijing Wandong Medical Technology's P/E ratio?
Beijing Wandong Medical Technology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Beijing Wandong Medical Technology?
Beijing Wandong Medical Technology runs a net profit margin of -20.2%, a gross margin of 22.6%, and an operating margin of -27.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Beijing Wandong Medical Technology generate?
Beijing Wandong Medical Technology reported revenue of ¥1.3B for fiscal year 2025, with net income of -¥228M and earnings per share (EPS) of -0.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Beijing Wandong Medical Technology pay a dividend?
Beijing Wandong Medical Technology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Beijing Wandong Medical Technology financially healthy?
Beijing Wandong Medical Technology carries a debt-to-equity ratio of 0.06x and a current ratio of 5.41x, with a market beta of -0.05. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Beijing Wandong Medical Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Beijing Wandong Medical Technology (600055) the key facts are: market cap ¥7.4B, revenue ¥1.3B, 52-week range 9.83-18.88. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Beijing Wandong Medical Technology's full fundamentals live
Get Beijing Wandong Medical Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.